- Metabolic Risk/Epidemiology
- Association of Uterine Leiomyoma with Type 2 Diabetes Mellitus in Young Women: A Population-Based Cohort Study
-
Ji-Hee Sung, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park
-
Diabetes Metab J. 2024;48(6):1105-1113. Published online August 19, 2024
-
DOI: https://doi.org/10.4093/dmj.2023.0444
-
-
 Abstract
 PDF Supplementary Material PubReader  ePub
- Background
We investigated the association between uterine leiomyoma (UL) and incident type 2 diabetes mellitus (T2DM) in young women.
Methods
A nationwide population-based cohort study of 2,541,550 women aged between 20 and 40 years was performed using the National Health Information Database. Cox proportional hazards models were used to analyze the risk of incident T2DM according to the presence of UL and myomectomy.
Results
The mean age was 29.70 years, and mean body mass index was 21.31 kg/m2. Among 2,541,550 participants, 18,375 (0.72%) women had UL. During a median 7.45 years of follow-up, 23,829 women (0.94%) were diagnosed with T2DM. The incidence of T2DM in women with UL (1.805/1,000 person-years) was higher than in those without UL (1.289/1,000 person-years). Compared with women without UL, women with UL had a higher risk of incident T2DM (hazard ratio, 1.216; 95% confidence interval [CI], 1.071 to 1.382). Women with UL who did not undergo myomectomy had a 1.505 times (95% CI, 1.297 to 1.748) higher risk for incident T2DM than women without UL. However, women with UL who underwent myomectomy did not have increased risk for incident T2DM.
Conclusion
Young women with UL were associated with a high risk of incident T2DM. In addition, myomectomy seemed to attenuate the risk for incident T2DM in young women with UL.
- Guideline/Fact Sheet
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
-
Jaehyun Bae, Eugene Han, Hye Won Lee, Cheol-Young Park, Choon Hee Chung, Dae Ho Lee, Eun-Hee Cho, Eun-Jung Rhee, Ji Hee Yu, Ji Hyun Park, Ji-Cheol Bae, Jung Hwan Park, Kyung Mook Choi, Kyung-Soo Kim, Mi Hae Seo, Minyoung Lee, Nan-Hee Kim, So Hun Kim, Won-Young Lee, Woo Je Lee, Yeon-Kyung Choi, Yong-ho Lee, You-Cheol Hwang, Young Sang Lyu, Byung-Wan Lee, Bong-Soo Cha, on Behalf of the Fatty Liver Research Group of the Korean Diabetes Association
-
Diabetes Metab J. 2024;48(6):1015-1028. Published online November 21, 2024
-
DOI: https://doi.org/10.4093/dmj.2024.0541
-
-
Abstract
PDFPubReader ePub
- Since the role of the liver in metabolic dysfunction, including type 2 diabetes mellitus, was demonstrated, studies on non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) have shown associations between fatty liver disease and other metabolic diseases. Unlike the exclusionary diagnostic criteria of NAFLD, MAFLD diagnosis is based on the presence of metabolic dysregulation in fatty liver disease. Renaming NAFLD as MAFLD also introduced simpler diagnostic criteria. In 2023, a new nomenclature, steatotic liver disease (SLD), was proposed. Similar to MAFLD, SLD diagnosis is based on the presence of hepatic steatosis with at least one cardiometabolic dysfunction. SLD is categorized into metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related/-associated liver disease, alcoholrelated liver disease, specific etiology SLD, and cryptogenic SLD. The term MASLD has been adopted by a number of leading national and international societies due to its concise diagnostic criteria, exclusion of other concomitant liver diseases, and lack of stigmatizing terms. This article reviews the diagnostic criteria, clinical relevance, and differences among NAFLD, MAFLD, and MASLD from a diabetologist’s perspective and provides a rationale for adopting SLD/MASLD in the Fatty Liver Research Group of the Korean Diabetes Association.
- Drug/Regimen
- Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial
-
Jie-Eun Lee, Seung Hee Yu, Sung Rae Kim, Kyu Jeung Ahn, Kee-Ho Song, In-Kyu Lee, Ho-Sang Shon, In Joo Kim, Soo Lim, Doo-Man Kim, Choon Hee Chung, Won-Young Lee, Soon Hee Lee, Dong Joon Kim, Sung-Rae Cho, Chang Hee Jung, Hyun Jeong Jeon, Seung-Hwan Lee, Keun-Young Park, Sang Youl Rhee, Sin Gon Kim, Seok O Park, Dae Jung Kim, Byung Joon Kim, Sang Ah Lee, Yong-Hyun Kim, Kyung-Soo Kim, Ji A Seo, Il Seong Nam-Goong, Chang Won Lee, Duk Kyu Kim, Sang Wook Kim, Chung Gu Cho, Jung Han Kim, Yeo-Joo Kim, Jae-Myung Yoo, Kyung Wan Min, Moon-Kyu Lee
-
Diabetes Metab J. 2024;48(4):730-739. Published online May 20, 2024
-
DOI: https://doi.org/10.4093/dmj.2023.0077
-
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular disease (CVD). This study aimed to evaluate the efficacy and safety of combination drugs consisting of metformin and atorvastatin, widely used as therapeutic agents for diabetes and dyslipidemia.
Methods
This randomized, double-blind, placebo-controlled, parallel-group and phase III multicenter study included adults with glycosylated hemoglobin (HbA1c) levels >7.0% and <10.0%, low-density lipoprotein cholesterol (LDL-C) >100 and <250 mg/dL. One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metformin+atorvastatin placebo), and atorvastatin group (atorvastatin+metformin placebo). The primary efficacy endpoints were the percent changes in HbA1c and LDL-C levels from baseline at the end of the treatment.
Results
After 16 weeks of treatment compared to baseline, HbA1c showed a significant difference of 0.94% compared to the atorvastatin group in the combination group (0.35% vs. −0.58%, respectively; P<0.0001), whereas the proportion of patients with increased HbA1c was also 62% and 15%, respectively, showing a significant difference (P<0.001). The combination group also showed a significant decrease in LDL-C levels compared to the metformin group (−55.20% vs. −7.69%, P<0.001) without previously unknown adverse drug events.
Conclusion
The addition of atorvastatin to metformin improved HbA1c and LDL-C levels to a significant extent compared to metformin or atorvastatin alone in diabetes and dyslipidemia patients. This study also suggested metformin’s preventive effect on the glucose-elevating potential of atorvastatin in patients with type 2 diabetes mellitus and dyslipidemia, insufficiently controlled with exercise and diet. Metformin and atorvastatin combination might be an effective treatment in reducing the CVD risk in patients with both diabetes and dyslipidemia because of its lowering effect on LDL-C and glucose.
- Guideline/Fact Sheet
- Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017
-
Eugene Han, Kyung-Do Han, Yong-ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park, on Behalf of Fatty Liver Research Group of the Korean Diabetes Association
-
Diabetes Metab J. 2023;47(3):347-355. Published online March 29, 2023
-
DOI: https://doi.org/10.4093/dmj.2022.0444
-
-
5,303
View
-
252
Download
-
12
Web of Science
-
16
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
This study investigated the changes of fatty liver disease prevalence in general Korean population.
Methods
This study analyzed data from the Korean National Health Insurance Service from 2009 to 2017 that included individuals aged 20 years or older who had undergone a medical health examination. Fatty liver disease was assessed using the fatty liver index (FLI). The disease severity was defined by FLI cutoff, ≥30 as moderate, and ≥60 as severe fatty liver disease.
Results
The prevalence of Korean adults aged 20 years or over with fatty liver disease (FLI ≥60) increased from 13.3% in 2009 to 15.5% in 2017 (P for trend <0.001). The increase in fatty liver disease prevalence was prominent in men (from 20.5% to 24.2%) and the young age (20 to 39 years) group (from 12.8% to 16.4%) (P for interaction <0.001). The prevalence of fatty liver disease was the highest in type 2 diabetes mellitus (T2DM, 29.6%) population compared to that of prediabetes or normoglycemia (10.0% and 21.8%) in 2017. The prevalence of fatty liver disease had statistically increased in individuals with T2DM and prediabetes (P for trend <0.001). Its prevalence increased more steeply in the young-aged population with T2DM, from 42.2% in 2009 to 60.1% in 2017. When applying a lower FLI cutoff (≥30) similar results were observed.
Conclusion
The prevalence of fatty liver disease in the Korean population has increased. Individuals who are young, male, and have T2DM are vulnerable to fatty liver disease.
-
Citations
Citations to this article as recorded by  - Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea
Min Gu Kang, Chang Hun Lee, Chen Shen, Jong Seung Kim, Ji Hyun Park
Journal of Hepatology.2024; 80(5): e216. CrossRef - Repeated detection of non‐alcoholic fatty liver disease increases the incidence risk of type 2 diabetes in young adults
Jin Hwa Kim, Young Sang Lyu, Mee Kyoung Kim, Sang Yong Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon
Diabetes, Obesity and Metabolism.2024; 26(1): 180. CrossRef - Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
Metabolism.2024; 152: 155789. CrossRef - Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
BMJ.2024; : e076388. CrossRef - Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
Scott L. Friedman
Diabetes & Metabolism Journal.2024; 48(2): 161. CrossRef - Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
Inha Jung, Dae-Jeong Koo, Won-Young Lee
Diabetes & Metabolism Journal.2024; 48(3): 327. CrossRef - Association between long working hours and metabolic dysfunction–associated steatotic liver disease: a nationwide population-based study in Korea
S.-U. Baek, J.-U. Won, Y.-M. Lee, J.-H. Yoon
Public Health.2024; 232: 188. CrossRef - Association between Dietary Quality and Non-Alcoholic Fatty Liver Disease in Korean Adults: A Nationwide, Population-Based Study Using the Korean Healthy Eating Index (2013–2021)
Seong-Uk Baek, Taeyeon Kim, Yu-Min Lee, Jong-Uk Won, Jin-Ha Yoon
Nutrients.2024; 16(10): 1516. CrossRef - Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
American Journal of Gastroenterology.2024;[Epub] CrossRef - Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
Cancers.2024; 16(18): 3161. CrossRef - Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Jaehyun Bae, Eugene Han, Hye Won Lee, Cheol-Young Park, Choon Hee Chung, Dae Ho Lee, Eun-Hee Cho, Eun-Jung Rhee, Ji Hee Yu, Ji Hyun Park, Ji-Cheol Bae, Jung Hwan Park, Kyung Mook Choi, Kyung-Soo Kim, Mi Hae Seo, Minyoung Lee, Nan-Hee Kim, So Hun Kim, Won-
Diabetes & Metabolism Journal.2024; 48(6): 1015. CrossRef - High-Sensitivity C-Reactive Protein Levels in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Alcohol-Associated Liver Disease (MetALD), and Alcoholic Liver Disease (ALD) with Metabolic Dysfunction
Seong-Uk Baek, Jin-Ha Yoon
Biomolecules.2024; 14(11): 1468. CrossRef - Reply to G. Wang et al
Joo-Hyun Park, Jung Yong Hong, Kyungdo Han
Journal of Clinical Oncology.2023; 41(32): 5070. CrossRef - The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review
Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca
Diagnostics.2023; 13(21): 3316. CrossRef - Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
Eugene Han, Yong-ho Lee
Clinical and Molecular Hepatology.2023; 29(4): 980. CrossRef - Approach to Fatty Liver Disease in Patients with Type 2 Diabetes
Ji Cheol Bae
The Journal of Korean Diabetes.2023; 24(3): 107. CrossRef
- Metabolic Risk/Epidemiology
- Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
-
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
-
Diabetes Metab J. 2023;47(2):220-231. Published online January 12, 2023
-
DOI: https://doi.org/10.4093/dmj.2021.0327
-
-
65,535
View
-
323
Download
-
14
Web of Science
-
13
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
We investigated whether metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with an elevated risk of all-cause and cardiovascular mortality using a large-scale health examination cohort.
Methods
A total of 394,835 subjects in the Kangbuk Samsung Health Study cohort were enrolled from 2002 to 2012. Participants were categorized by the presence of nonalcoholic fatty liver disease (NAFLD) and MAFLD as follows: normal subjects; patients with both NAFLD and MAFLD; patients with NAFLD only; and patients with MAFLD only. Cox proportional hazards models were used to analyze the risk of mortality.
Results
During a median 5.7 years of follow-up, 20.69% was patients with both NAFLD and MAFLD, 1.51% was patients with NAFLD only, and 4.29% was patients with MAFLD only. All-cause and cardiovascular death was higher in patients with MAFLD than those without MAFLD (P<0.001, respectively). In patients with MAFLD only, the hazard ratio (HR) of all-cause and cardiovascular death was 1.35 (95% confidence interval [CI], 1.13 to 1.60) and 1.90 (95% CI, 1.26 to 2.88) after adjusting for age, which lost its statistical significance by multivariable adjustments. Compared to patients with less than two components of metabolic dysfunction, patients with more than two components of metabolic dysfunction were a higher risk of cardiovascular death (HR, 2.05; 95% CI, 1.25 to 3.38) and only women with more than two components of metabolic dysfunction were a higher risk of all-cause death (HR, 1.44; 95% CI, 1.02 to 2.03).
Conclusion
MAFLD criteria could identify a high-risk group for all-cause and cardiovascular death.
-
Citations
Citations to this article as recorded by - Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
Metabolism.2024; 152: 155789. CrossRef - Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
BMJ.2024; : e076388. CrossRef - Sex differences in mortality and liver‐related events in non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
Huimin Zhou, Haiyan Chen, Hanxiao Lu, Bo Wu, Shuo Zhang, Yuanlong Gu, Guangwen Zhou, Jie Xiang, Jun Yang
Liver International.2024; 44(7): 1600. CrossRef - Association between dietary carbohydrate to fiber ratio and metabolic dysfunction associated fatty liver disease in adults: evidence from the NHANES 2017–2020
Zhenmin Liu, Taiyong Fang
Journal of Health, Population and Nutrition.2024;[Epub] CrossRef - NAFLD and MAFLD independently increase the risk of major adverse cardiovascular events (MACE): a 20-year longitudinal follow-up study from regional Australia
Karl Vaz, William Kemp, Ammar Majeed, John Lubel, Dianna J. Magliano, Kristen M. Glenister, Lisa Bourke, David Simmons, Stuart K. Roberts
Hepatology International.2024; 18(4): 1135. CrossRef - Clinical outcomes of MAFLD versus NAFLD: A meta‐analysis of observational studies
Grazia Pennisi, Giuseppe Infantino, Ciro Celsa, Gabriele Di Maria, Marco Enea, Marco Vaccaro, Roberto Cannella, Carlo Ciccioli, Claudia La Mantia, Alessandro Mantovani, Francesco Mercurio, Herbert Tilg, Giovanni Targher, Vito Di Marco, Calogero Cammà, Sal
Liver International.2024; 44(11): 2939. CrossRef - Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and e
Jae Hyun Bae
Clinical and Molecular Hepatology.2024; 30(4): 665. CrossRef - Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis
Ghazala S Virk, Jaahnavi Vajje, Nausheen K Virk, Raam Mannam, Wajeeh Rehman, Naglaa G Ghobriel , Irfan-ud-din Mian, Muhammad Usama
Cureus.2023;[Epub] CrossRef - Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study
Zhi-Qin Xie, Hong-Xia Li, Bing-Kun Wang, Zhao-Ming Yang, Zi-Yu Zhang, Wen-Liang Tan, Wen-Xin Li, Qing-Bin Wang, Lei Yang, Hong-Kai Zhuang, Chen-Wei Tang, Chang-Zhen Shang, Ya-Jin Chen
European Journal of Internal Medicine.2023; 110: 62. CrossRef - Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
Han Na Jung, Chang Hee Jung
Diabetes & Metabolism Journal.2023; 47(2): 198. CrossRef - Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
Metabolism.2023; 145: 155612. CrossRef - Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes
Karl Vaz, Daniel Clayton-Chubb, Ammar Majeed, John Lubel, David Simmons, William Kemp, Stuart K. Roberts
Hepatology International.2023; 17(5): 1082. CrossRef - Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Soyeon Shin, Jaeyoung Kim, Ju Yeon Lee, Jun Kim, Chang-Myung Oh
Journal of Obesity & Metabolic Syndrome.2023; 32(4): 289. CrossRef
- Metabolic Risk/Epidemiology
- Postprandial Free Fatty Acids at Mid-Pregnancy Increase the Risk of Large-for-Gestational-Age Newborns in Women with Gestational Diabetes Mellitus
-
So-Yeon Kim, Young Shin Song, Soo-Kyung Kim, Yong-Wook Cho, Kyung-Soo Kim
-
Diabetes Metab J. 2022;46(1):140-148. Published online August 9, 2021
-
DOI: https://doi.org/10.4093/dmj.2021.0023
-
-
6,029
View
-
175
Download
-
3
Web of Science
-
3
Crossref
-
 Graphical Abstract
Abstract
PDFSupplementary MaterialPubReader ePub
 - Background
To investigate the association between free fatty acid (FFA) level at mid-pregnancy and large-for-gestational-age (LGA) newborns in women with gestational diabetes mellitus (GDM).
Methods
We enrolled 710 pregnant women diagnosed with GDM from February 2009 to October 2016. GDM was diagnosed by a ‘two-step’ approach with Carpenter and Coustan criteria. We measured plasma lipid profiles including fasting and 2-hour postprandial FFA (2h-FFA) levels at mid-pregnancy. LGA was defined if birthweights of newborns were above the 90th percentile for their gestational age.
Results
Mean age of pregnant women in this study was 33.1 years. Mean pre-pregnancy body mass index (BMI) was 22.4 kg/m2. The prevalence of LGA was 8.3% (n=59). Levels of 2h-FFA were higher in women who delivered LGA newborns than in those who delivered non-LGA newborns (416.7 μEq/L vs. 352.5 μEq/L, P=0.006). However, fasting FFA was not significantly different between the two groups. The prevalence of delivering LGA newborns was increased with increasing tertile of 2h-FFA (T1, 4.3%; T2, 9.8%; T3, 10.7%; P for trend <0.05). After adjustment for maternal age, pre-pregnancy BMI, and fasting plasma glucose, the highest tertile of 2h-FFA was 2.38 times (95% confidence interval, 1.11 to 5.13) more likely to have LGA newborns than the lowest tertile. However, there was no significant difference between groups according to fasting FFA tertiles.
Conclusion
In women with GDM, a high 2h-FFA level (but not fasting FFA) at mid-pregnancy is associated with an increasing risk of delivering LGA newborns.
-
Citations
Citations to this article as recorded by - Advances in free fatty acid profiles in gestational diabetes mellitus
Haoyi Du, Danyang Li, Laura Monjowa Molive, Na Wu
Journal of Translational Medicine.2024;[Epub] CrossRef - Modulation of gut microbiota and lipid metabolism in rats fed high-fat diets by Ganoderma lucidum triterpenoids
Aijun Tong, Weihao Wu, Zhengxin Chen, Jiahui Wen, Ruibo Jia, Bin Liu, Hui Cao, Chao Zhao
Current Research in Food Science.2023; 6: 100427. CrossRef - Fetal Abdominal Obesity Detected at 24 to 28 Weeks of Gestation Persists until Delivery Despite Management of Gestational Diabetes Mellitus (Diabetes Metab J 2021;45:547-57)
Wonjin Kim, Soo Kyung Park, Yoo Lee Kim
Diabetes & Metabolism Journal.2021; 45(6): 970. CrossRef
- Basic Research
- Role of Autophagy in Granulocyte-Colony Stimulating Factor Induced Anti-Apoptotic Effects in Diabetic Cardiomyopathy
-
Guang-Yin Shen, Jeong-Hun Shin, Yi-Sun Song, Hyun-Woo Joo, In-Hwa Park, Jin-Hee Seong, Na-Kyoung Shin, A-Hyeon Lee, Young Jong Cho, Yonggu Lee, Young-Hyo Lim, Hyuck Kim, Kyung-Soo Kim
-
Diabetes Metab J. 2021;45(4):594-605. Published online February 26, 2021
-
DOI: https://doi.org/10.4093/dmj.2020.0049
-
-
8,283
View
-
163
Download
-
5
Web of Science
-
4
Crossref
-
Graphical Abstract
Abstract
PDFSupplementary MaterialPubReader ePub
 - Background
We previously, reported that granulocyte-colony stimulating factor (G-CSF) reduces cardiomyocyte apoptosis in diabetic cardiomyopathy. However, the underlying mechanisms are not yet fully understood. Therefore, we investigated whether the mechanisms underlying of the anti-apoptotic effects of G-CSF were associated with autophagy using a rat model of diabetic cardiomyopathy.
Methods
Diabetic cardiomyopathy was induced in rats through a high-fat diet combined with low-dose streptozotocin and the rats were then treated with G-CSF for 5 days. Rat H9c2 cardiac cells were cultured under high glucose conditions as an in vitro model of diabetic cardiomyopathy. The extent of apoptosis and protein levels related to autophagy (Beclin-1, microtubule-binding protein light chain 3 [LC3]-II/LC3-I ratio, and P62) were determined for both models. Autophagy determination was performed using an Autophagy Detection kit.
Results
G-CSF significantly reduced cardiomyocyte apoptosis in the diabetic myocardium in vivo and led to an increase in Beclin-1 level and the LC3-II/LC3-I ratio, and decreased P62 level. Similarly, G-CSF suppressed apoptosis, increased Beclin-1 level and LC3-II/LC3-I ratio, and decreased P62 level in high glucose-induced H9c2 cardiac cells in vitro. These effects of G-CSF were abrogated by 3-methyladenine, an autophagy inhibitor. In addition, G-CSF significantly increased autophagic flux in vitro.
Conclusion
Our results suggest that the anti-apoptotic effect of G-CSF might be significantly associated with the up-regulation of autophagy in diabetic cardiomyopathy.
-
Citations
Citations to this article as recorded by - Targeting autophagy in diabetic cardiomyopathy: From molecular mechanisms to pharmacotherapy
Jie Li, Yingying Xie, Shuwen Zheng, Haoming He, Zhe Wang, Xuexi Li, Siqi Jiao, Dong Liu, Furong Yang, Hailing Zhao, Ping Li, Yihong Sun
Biomedicine & Pharmacotherapy.2024; 175: 116790. CrossRef - Knockout of C1q/tumor necrosis factor-related protein-9 aggravates cardiac fibrosis in diabetic mice by regulating YAP-mediated autophagy
Shiyan Ruan, Jun Li, Shengyun Lei, Shaomeng Zhang, Dan Xu, Anju Zuo, Linxi Li, Yuan Guo
Frontiers in Pharmacology.2024;[Epub] CrossRef - Ginkgo biloba extract protects against diabetic cardiomyopathy by restoring autophagy via adenosine monophosphate‐activated protein kinase/mammalian target of the rapamycin pathway modulation
Xueyao Yang, Xin Zhao, Yanfei Liu, Yue Liu, Libo Liu, Ziyu An, Haoran Xing, Jinfan Tian, Xiantao Song
Phytotherapy Research.2023; 37(4): 1377. CrossRef - Perspectives for Forkhead box transcription factors in diabetic cardiomyopathy: Their therapeutic potential and possible effects of salvianolic acids
Ronghui Han, Hemeng Huang, Weiyi Xia, Jingjin Liu, Hui Luo, Jing Tang, Zhengyuan Xia
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
- Basic Research
- Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
-
Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
-
Diabetes Metab J. 2021;45(2):260-269. Published online July 10, 2020
-
DOI: https://doi.org/10.4093/dmj.2019.0191
-
-
11,145
View
-
223
Download
-
11
Web of Science
-
10
Crossref
-
Graphical Abstract
Abstract
PDFSupplementary MaterialPubReader ePub
 -
Background
Umbilical cord-mesenchymal stem cell-conditioned medium (UC-MSC-CM) has emerged as a promising cell-free therapy. The aim of this study was to explore the therapeutic effects of UC-MSC-CM on insulin resistance in C2C12 cell.
Methods
Insulin resistance was induced by palmitate. Effects of UC-MSC-CM on insulin resistance were evaluated using glucose uptake, glucose transporter type 4 (GLUT4) translocation, the insulin-signaling pathway, and mitochondrial contents and functions in C2C12 cell.
Results
Glucose uptake was improved by UC-MSC-CM. UC-MSC-CM treatment increased only in membranous GLUT4 expression, not in cytosolic GLUT4 expression. It restored the insulin-signaling pathway in insulin receptor substrate 1 and protein kinase B. Mitochondrial contents evaluated by mitochondrial transcription factor A, mitochondrial DNA copy number, and peroxisome proliferator-activated receptor gamma coactivator 1-alpha were increased by UC-MSC-CM. In addition, UC-MSC-CM significantly decreased mitochondrial reactive oxygen species and increased fatty acid oxidation and mitochondrial membrane potential. There was no improvement in adenosine triphosphate (ATP) contents, but ATP synthesis was improved by UC-MSC-CM. Cytokine and active factor analysis of UC-MSC-CM showed that it contained many regulators inhibiting insulin resistance.
Conclusion
UC-MSC-CM improves insulin resistance with multiple mechanisms in C2C12 cell.
-
Citations
Citations to this article as recorded by - Wharton’s Jelly Mesenchymal Stem Cell Conditioned Medium Ameliorates Diabetes‐Induced Testicular Damage and Sperm Abnormalities by Mitigating Oxidative Stress, Apoptosis, and Inflammation
Mojtaba Sargazi, Narges Karbalaei, Saied Karbalay-Doust, Sara Keshtgar, Zohre Aghaei, Pasquale Marrazzo
Stem Cells International.2024;[Epub] CrossRef - Secretome Derived from Mesenchymal Stem/Stromal Cells: A Promising Strategy for Diabetes and its Complications
ling li, Siyu Hua, Lianghui You, Tianying Zhong
Current Stem Cell Research & Therapy.2024; 19(10): 1328. CrossRef - Neurotransmitters in Type 2 Diabetes and the Control of Systemic and Central Energy Balance
Amnah Al-Sayyar, Maha M. Hammad, Michayla R. Williams, Mohammed Al-Onaizi, Jehad Abubaker, Fawaz Alzaid
Metabolites.2023; 13(3): 384. CrossRef - Neuroprotective Effect of Wharton’s Jelly-Derived Mesenchymal Stem Cell-Conditioned Medium (WJMSC-CM) on Diabetes-Associated Cognitive Impairment by Improving Oxidative Stress, Neuroinflammation, and Apoptosis
Zohre Aghaei, Narges Karbalaei, Mohammad Reza Namavar, Masoud Haghani, Mahboobeh Razmkhah, Mahdi Khorsand Ghaffari, Marzieh Nemati, Andrea Ballini
Stem Cells International.2023; 2023: 1. CrossRef - Mesenchymal-Stem Cell-Derived Conditioned Media Versus Exosomes in the Treatment of Rat Model of Polycystic Ovary: An Attempt to Understand the Underlying Mechanisms (Biochemical and Histological Study)
Soha Abd-elkawy Abd-elwahab, Noura Hassan Khamis, Rehab Ahmed Rifaai, Nashwa Fathy Gamal El-Tahawy, Randa Ahmed Ibrahim
Microscopy and Microanalysis.2023; 29(3): 1244. CrossRef - Therapeutic Potential of Mesenchymal Stem Cell‐Derived Conditioned Medium for Diabetes Mellitus and Related Complications
Basak Isildar, Serbay Ozkan, Meral Koyuturk
Advanced Therapeutics.2023;[Epub] CrossRef - Treatment of type 2 diabetes mellitus with stem cells and antidiabetic drugs: a dualistic and future-focused approach
Priyamvada Amol Arte, Kanchanlata Tungare, Mustansir Bhori, Renitta Jobby, Jyotirmoi Aich
Human Cell.2023; 37(1): 54. CrossRef - Perinatal Stem Cell Therapy to Treat Type 1 Diabetes Mellitus: A Never-Say-Die Story of Differentiation and Immunomodulation
Francesca Paris, Valeria Pizzuti, Pasquale Marrazzo, Andrea Pession, Francesco Alviano, Laura Bonsi
International Journal of Molecular Sciences.2022; 23(23): 14597. CrossRef - Mesenchymal Stem Cell-Derived Apoptotic Bodies: Biological Functions and Therapeutic Potential
Huixue Tang, Huikun Luo, Zihan Zhang, Di Yang
Cells.2022; 11(23): 3879. CrossRef - Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach
Andreia Gomes, Pedro Coelho, Raquel Soares, Raquel Costa
Cell and Tissue Research.2021; 385(3): 497. CrossRef
- Technology/Device
- Role of MicroRNA-34a in Anti-Apoptotic Effects of Granulocyte-Colony Stimulating Factor in Diabetic Cardiomyopathy
-
In-Hwa Park, Yi-Sun Song, Hyun-Woo Joo, Guang-Yin Shen, Jin-Hee Seong, Na-Kyoung Shin, Young Jong Cho, Yonggu Lee, Jeong Hun Shin, Young-Hyo Lim, Hyuck Kim, Kyung-Soo Kim
-
Diabetes Metab J. 2020;44(1):173-185. Published online April 23, 2019
-
DOI: https://doi.org/10.4093/dmj.2018.0211
-
-
6,306
View
-
81
Download
-
13
Web of Science
-
11
Crossref
-
Abstract
PDFSupplementary MaterialPubReader
- Background
Recent studies have shown that microRNAs (miRNAs) are involved in the process of cardiomyocyte apoptosis. We have previously reported that granulocyte-colony stimulating factor (G-CSF) ameliorated diastolic dysfunction and attenuated cardiomyocyte apoptosis in a rat model of diabetic cardiomyopathy. In this study, we hypothesized a regulatory role of cardiac miRNAs in the mechanism of the anti-apoptotic effect of G-CSF in a diabetic cardiomyopathy rat model. MethodsRats were given a high-fat diet and low-dose streptozotocin injection and then randomly allocated to receive treatment with either G-CSF or saline. H9c2 rat cardiomyocytes were cultured under a high glucose (HG) condition to induce diabetic cardiomyopathy in vitro. We examined the extent of apoptosis, miRNA expression, and miRNA target genes in the myocardium and H9c2 cells. ResultsG-CSF treatment significantly decreased apoptosis and reduced miR-34a expression in diabetic myocardium and H9c2 cells under the HG condition. G-CSF treatment also significantly increased B-cell lymphoma 2 (Bcl-2) protein expression as a target for miR-34a. In addition, transfection with an miR-34a mimic significantly increased apoptosis and decreased Bcl-2 luciferase activity in H9c2 cells. ConclusionOur results indicate that G-CSF might have an anti-apoptotic effect through down-regulation of miR-34a in a diabetic cardiomyopathy rat model.
-
Citations
Citations to this article as recorded by - The study of the mechanism of non-coding RNA regulation of programmed cell death in diabetic cardiomyopathy
Bingrui Zhang, Hua Wu, Jingwen Zhang, Cong Cong, Lin Zhang
Molecular and Cellular Biochemistry.2024; 479(7): 1673. CrossRef - Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction
Elisabeth A. Jalink, Amber W. Schonk, Reinier A. Boon, Rio P. Juni
Frontiers in Cardiovascular Medicine.2024;[Epub] CrossRef - The interregulatory circuit between non-coding RNA and apoptotic signaling in diabetic cardiomyopathy
Hao Wu, Yan Liu, Chunli Liu
Non-coding RNA Research.2024; 9(4): 1080. CrossRef - Dynamic interplay of microRNA in diseases and therapeutic
Neha Kargutkar, Priya Hariharan, Anita Nadkarni
Clinical Genetics.2023; 103(3): 268. CrossRef - LGR5+ Intestinal Stem Cells Display Sex-Dependent Radiosensitivity
Ryan C. Zitter, Rishi Man Chugh, Payel Bhanja, Bruce F. Kimler, Subhrajit Saha
Cells.2023; 13(1): 46. CrossRef - Female Mice are More Resistant to the Mixed-Field (67% Neutron + 33% Gamma) Radiation-Induced Injury in Bone Marrow and Small Intestine than Male Mice due to Sustained Increases in G-CSF and the Bcl-2/Bax Ratio and Lower miR-34a and MAPK Activation
Juliann G. Kiang, Georgetta Cannon, Matthew G. Olson, Joan T. Smith, Marsha N. Anderson, Min Zhai, M. Victoria Umali, Kevin Ho, Connie Ho, Wanchang Cui, Mang Xiao
Radiation Research.2022;[Epub] CrossRef - Potential Role of Natural Plant Medicine Cyclocarya paliurus in the Treatment of Type 2 Diabetes Mellitus
Han Wang, Cheng Tang, Zezheng Gao, Yishan Huang, Boxun Zhang, Jiahua Wei, Linhua Zhao, Xiaolin Tong, Yong Xu
Journal of Diabetes Research.2021; 2021: 1. CrossRef - Ghrelin, a novel therapy, corrects cytokine and NF-κB-AKT-MAPK network and mitigates intestinal injury induced by combined radiation and skin-wound trauma
Juliann G. Kiang, Joan T. Smith, Georgetta Cannon, Marsha N. Anderson, Connie Ho, Min Zhai, Wanchang Cui, Mang Xiao
Cell & Bioscience.2020;[Epub] CrossRef - Evaluation of biomarkers in liver following Solanum melongena green calyx administration in diabetic rats
Shiva Roshankhah, Ahmad Shabanizadeh, Amir Abdolmaleki, Mohammad Reza Gholami, Mohammad Reza Salahshoor
Journal of Diabetes & Metabolic Disorders.2020; 19(2): 1115. CrossRef - Diabetic cardiomyopathy: definition, diagnosis criteria, treatment directions and prevention of heart failure
N. A. Koziolova, P. G. Karavaev, A. S. Veklich
South Russian Journal of Therapeutic Practice.2020; 1(2): 93. CrossRef - The Potential Role of MicroRNA in Diabetic Cardiomyopathy
Jin Hwa Kim
Diabetes & Metabolism Journal.2020; 44(1): 54. CrossRef
- Clinical Diabetes & Therapeutics
- Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
-
Kyung-Soo Kim, Byung-Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong-Soo Cha, Cheol-Young Park
-
Diabetes Metab J. 2019;43(2):127-143. Published online April 15, 2019
-
DOI: https://doi.org/10.4093/dmj.2019.0034
-
-
9,471
View
-
174
Download
-
28
Web of Science
-
37
Crossref
-
Abstract
PDFPubReader
Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes. -
Citations
Citations to this article as recorded by - Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
BMJ.2024; : e076388. CrossRef - The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes
Morteza Aghajanpoor, Mehrzad Gholampourdehaki, Reza Mosaed, Iraj Mirzaii-Dizgah, Afsaneh Vosughi
Annals of Military and Health Sciences Research.2024;[Epub] CrossRef - Research Progress of Traditional Chinese Medicine and Western Medicine on Non-Alcoholic Fatty Liver Disease
强江 郭
Advances in Clinical Medicine.2024; 14(03): 561. CrossRef - Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
Alhussain Yasin, Madison Nguyen, Angad Sidhu, Priyanka Majety, Jared Spitz, Amon Asgharpour, Mohammad S. Siddiqui, Laurence S. Sperling, Arshed A. Quyyumi, Anurag Mehta
Diabetes Research and Clinical Practice.2024; 211: 111650. CrossRef - Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Rizwana Parveen, Shadan Hussain, Sparsh Saini, Parvej Khan, Nilanjan Saha, Nidhi
Expert Opinion on Pharmacotherapy.2024; 25(7): 925. CrossRef - Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes
Keyvan Ghalandari, Mojtaba Shabani, Ali Khajehlandi, Amin Mohammadi
Archives of Physiology and Biochemistry.2023; 129(1): 76. CrossRef - Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes & Metabolism Journal.2023; 47(2): 220. CrossRef - Comparative antihypertensive efficacy of combinations of azilsartan medoxomil or olmesartan medoxomil with amlodipine in patients with arterial hypertension, type 2 diabetes mellitus and non-alcoholic fatty liver disease
I. А. Lukonin, V. V. Skibitsky, A. V. Fendrikova, A. V. Skibitsky, I. A. Antipov
South Russian Journal of Therapeutic Practice.2023; 4(1): 68. CrossRef - An Ethyl Acetate Extract of Eryngium carlinae Inflorescences Attenuates Oxidative Stress and Inflammation in the Liver of Streptozotocin-Induced Diabetic Rats
Cristian M. Trejo-Hurtado, Cinthia I. Landa-Moreno, Jenaro Lemus-de la Cruz, Donovan J. Peña-Montes, Rocío Montoya-Pérez, Rafael Salgado-Garciglia, Salvador Manzo-Avalos, Christian Cortés-Rojo, Juan Luis Monribot-Villanueva, José Antonio Guerrero-Analco,
Antioxidants.2023; 12(6): 1235. CrossRef - Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus
Iu.G. Samoilova, A.E. Stankova, M.V. Matveeva, O.E. Vaizova, D.V. Podchinenova, D.A. Kudlay, T.A. Filippova, I.R. Grishkevich
Profilakticheskaya meditsina.2023; 26(12): 95. CrossRef - Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241. CrossRef - Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
Obesity.2022; 30(6): 1279. CrossRef - Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-Calculate Marker for All-Cause and Cardiovascular Mortality
Kyung-Soo Kim, Sangmo Hong, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park
Journal of General Internal Medicine.2022; 37(16): 4153. CrossRef - Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
Kyung-Soo Kim
The Journal of Korean Diabetes.2022; 23(2): 83. CrossRef - Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang
Frontiers in Pharmacology.2022;[Epub] CrossRef - Intestinal microbiota in the treatment of metabolically associated fatty liver disease
Ji-Shuai Wang, Jin-Chun Liu
World Journal of Clinical Cases.2022; 10(31): 11240. CrossRef - Efficiency of combined antihypertensive pharmacotherapy in patients with arterial hypertension, combined with type 2 diabetes mellitus and non-alcoholic fatty liver disease
I. A. Lukonin, V. V. Skibitsky, A. V. Fendrikova, I. I. Pavlyuchenko, K. Yu. Lazarev, F. A. Kovalenko
Systemic Hypertension.2022; 19(1): 31. CrossRef - Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
Nutrients.2022; 14(23): 4994. CrossRef - Pluchea indica Leaf Extract Alleviates Dyslipidemia and Hepatic Steatosis by Modifying the Expression of Lipid Metabolism-Related Genes in Rats Fed a High Fat-High Fructose Diet
Patcharin Singdam, Jarinyaporn Naowaboot, Laddawan Senggunprai, Kampeebhorn Boonloh, Patchareewan Pannangpetch
Preventive Nutrition and Food Science.2022; 27(4): 384. CrossRef - NAFLDin type 2 diabetes mellitus: Still many challenging questions
Simona Cernea, Itamar Raz
Diabetes/Metabolism Research and Reviews.2021;[Epub] CrossRef - Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
Diabetes & Metabolism Journal.2021; 45(2): 260. CrossRef - Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes Therapy.2021; 12(1): 171. CrossRef - Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
Sook Jung Lee, Byung-Wan Lee
The Journal of Korean Diabetes.2021; 22(1): 38. CrossRef - Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14. CrossRef - NAFLD and its link with diabetes: Why we should be worried
Louise Cremonesini, Emma Harkin
Independent Nurse.2021; 2021(8): 20. CrossRef - Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
Diabetes & Metabolism Journal.2021; 45(5): 698. CrossRef - Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh
Cardiovascular Diabetology.2020;[Epub] CrossRef - Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
Rohit Loomba, Erin Morgan, Lynnetta Watts, Shuting Xia, Lisa A Hannan, Richard S Geary, Brenda F Baker, Sanjay Bhanot
The Lancet Gastroenterology & Hepatology.2020; 5(9): 829. CrossRef - Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
Medicine.2020; 99(33): e21038. CrossRef - Metabolic liver disease in diabetes – From mechanisms to clinical trials
Bedair Dewidar, Sabine Kahl, Kalliopi Pafili, Michael Roden
Metabolism.2020; 111: 154299. CrossRef - Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
Siôn A. Parry, Leanne Hodson
Advances in Therapy.2020; 37(4): 1381. CrossRef -
Diabetes and Metabolism Journal in 2020: Good to Great
In-Kyung Jeong
Diabetes & Metabolism Journal.2020; 44(1): 1. CrossRef - Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
Diabetes & Metabolism Journal.2020; 44(3): 382. CrossRef - Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies
Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen
Pharmacological Research.2020; 159: 104984. CrossRef - Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430. CrossRef - Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
Baodi Xing, Yuhang Zhao, Bingzi Dong, Yue Zhou, Wenshan Lv, Wenjuan Zhao
Journal of Diabetes Investigation.2020; 11(5): 1238. CrossRef - Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
Molecular and Cellular Endocrinology.2019; 498: 110539. CrossRef
- Complications
- Higher Prevalence and Progression Rate of Chronic Kidney Disease in Elderly Patients with Type 2 Diabetes Mellitus
-
Kyung-Soo Kim, Seok Won Park, Yong-Wook Cho, Soo-Kyung Kim
-
Diabetes Metab J. 2018;42(3):224-232. Published online May 31, 2018
-
DOI: https://doi.org/10.4093/dmj.2017.0065
-
-
6,337
View
-
84
Download
-
33
Web of Science
-
40
Crossref
-
Abstract
PDFPubReader
- Background
To evaluate the prevalence of chronic kidney disease (CKD) and progression rate to CKD in elderly patients with type 2 diabetes mellitus (T2DM). MethodsWe investigated the medical records of 190 elderly patients (65 years or older) with T2DM from 2005 to 2011 in 6-month increments. Mean follow-up duration was 64.5 months. CKD was defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 and/or the presence of albuminuria. ResultsThe mean age was 70.4 years and mean diabetes duration was 10.6 years. Among all the participants, 113 patients (59.5%) had CKD. The eGFR was significantly decreased between baseline (65.7±15.0 mL/min/1.73 m2) and the end of follow-up (52.7±17.5 mL/min/1.73 m2, P<0.001). At the end of follow-up, the prevalence of eGFR <60 mL/min/1.73 m2 had increased by 61.6% (at baseline, 44.2%). Furthermore, in patients with eGFR ≥60 mL/min/1.73 m2, the progression rate to more than CKD stage 3 was 39.6% at the end of follow-up; 30.2% of elderly diabetic patients had progressed to albuminuria from normoalbuminuria. Kaplan-Meier analysis showed that the time interval to worsening nephropathy was significantly shorter in elderly patients with diabetes duration ≥10 years than in those with diabetes duration <5 years (P=0.018). ConclusionCKD was commonly observed in older patients with T2DM, and the progression rate to CKD is also high. Consequently, it is important to identify and manage CKD as early as possible in elderly patients with T2DM, especially in those with diabetes duration ≥10 years.
-
Citations
Citations to this article as recorded by - Assessing heatwave effects on disabled persons in South Korea
Yeji Kang, Ingul Baek, Jongchul Park
Scientific Reports.2024;[Epub] CrossRef - Epidemiological patterns of chronic kidney disease attributed to type 2 diabetes from 1990-2019
Xiaoxiao Ding, Xiang Li, Yun Ye, Jing Jiang, Mengsang Lu, Lv Shao
Frontiers in Endocrinology.2024;[Epub] CrossRef - Medical database analysis of the association between kidney function and achievement of glycemic control in older Japanese adults with type 2 diabetes who started with oral antidiabetic drugs
Ryo Suzuki, Kiyoyasu Kazumori, Tatsuya Usui, Masahiko Shinohara
Journal of Diabetes Investigation.2024; 15(8): 1057. CrossRef - Associations between diabetes mellitus and subsequent non-communicable diseases in Indonesia
Jasmine A. Dwi Pratiwi, Chun-Ta Huang, Nirmin F. Juber, Jason J. Liu
Discover Social Science and Health.2024;[Epub] CrossRef - Proteinuria as a Critical Indicator of Kidney Dysfunction in Type 2 Diabetes Patients: Insights From a Cross-Sectional Study
Ritah Kiconco, Joash Okoboi, Samuel Mwesige, Kizito Muwonge, Robert Kinobe, Robert Kalyesubula, Gertrude N Kiwanuka
Cureus.2024;[Epub] CrossRef - Prevalence, risk factors, and comorbidities of type 2 diabetes among COPD patients at a Bhubaneswar secondary care hospital
Shritam Das, Braja Sundar Barik, Gurudutta Dash, Sudatta Chandan, Minaketan Barik, Nadeem Hussain, Tahziba Hussain, Bhawna Gupta, Sanghamitra Pati
International Journal of Diabetes in Developing Countries.2024;[Epub] CrossRef - Compound impact of heatwaves on vulnerable groups considering age, income, and disability
Yeji Kang, Jongchul Park, Dong-Ho Jang
Scientific Reports.2024;[Epub] CrossRef - Association of Uterine Leiomyoma with Type 2 Diabetes Mellitus in Young Women: A Population-Based Cohort Study
Ji-Hee Sung, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park
Diabetes & Metabolism Journal.2024; 48(6): 1105. CrossRef - Combination of Risks of BMI and Health-Related Lifestyles on Kidney Function in the Prediabetic Japanese Population: A Prospective Cohort Study
Jou-Yin Chen, Shiqi Deng, Yukiko Wagatsuma
International Journal of Environmental Research and Public Health.2023; 20(7): 5338. CrossRef - Hormonal imbalance in patients with chronic renal failure in the pre-dialysis and dialysis periods (part1)
I.P. Katerenchuk, S.T. Rustamyan, V.V. Talash, T.I. Yarmola
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2023; 19(1): 65. CrossRef - The Beneficial Effect of Glycemic Control against Adverse Outcomes in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Dong-Hwa Lee
Diabetes & Metabolism Journal.2023; 47(4): 484. CrossRef - Association Between Continuous Glucose Monitoring-Derived Glycemia Risk Index and Albuminuria in Type 2 Diabetes
Jee Hee Yoo, Ji Yoon Kim, Jae Hyeon Kim
Diabetes Technology & Therapeutics.2023; 25(10): 726. CrossRef - Global burden and influencing factors of chronic kidney disease due to type 2 diabetes in adults aged 20–59 years, 1990–2019
Dandan Xie, Tianpeng Ma, Haoliang Cui, Jing Li, Aihua Zhang, Zhifeng Sheng, Yiqiang Xie
Scientific Reports.2023;[Epub] CrossRef - Effectiveness of Early Advanced Glycation End Product Accumulation Testing in the Diagnosis of Diabetes: A Health Risk Factor Analysis Using the Body Mass Index as a Moderator
Yi Zhang, Tian Jiang, Chao Liu, Honglin Hu, Fang Dai, Li Xia, Qiu Zhang
Frontiers in Endocrinology.2022;[Epub] CrossRef - Causal association pathways between fetuin-A and kidney function: a mediation analysis
Philip Etabee Bassey, Pawin Numthavaj, Sasivimol Rattanasiri, Piyamitr Sritara, Mark McEvoy, Boonsong Ongphiphadhanakul, Ammarin Thakkinstian
Journal of International Medical Research.2022;[Epub] CrossRef - Advanced glycation end products and diabetes and other metabolic indicators
Tian Jiang, Yi Zhang, Fang Dai, Chao Liu, Honglin Hu, Qiu Zhang
Diabetology & Metabolic Syndrome.2022;[Epub] CrossRef - Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies
Theocharis Koufakis, Maria Grammatiki, Kalliopi Kotsa
Maturitas.2021; 143: 118. CrossRef - Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes Therapy.2021; 12(1): 171. CrossRef - Chronic kidney disease progression in aged patients
Murat Tuğcu, Dilek Barutçu Ataş
International Urology and Nephrology.2021; 53(12): 2619. CrossRef - Factors determining the clinical significance of dipeptidyl peptidase-4 inhibitors in the treatment of elderly patients with type 2 diabetes mellitus
I. V. Glinkina, A. V. Balashova, A. S. Shyman, A. V. Oderij, S. A. Khan, G. E. Runova, T. B. Morgunova, V. V. Fadeev
Meditsinskiy sovet = Medical Council.2021; (7): 56. CrossRef - Effect of Oral carnosine supplementation on urinary TGF-β in diabetic nephropathy: a randomized controlled trial
Narongrit Siriwattanasit, Bancha Satirapoj, Ouppatham Supasyndh
BMC Nephrology.2021;[Epub] CrossRef - Estimation of the prevalence of type 2 diabetes in combination with diabetic kidney disease and identification of the associated factors in patients attending primary hospitals in Anhui Province, China
Li Xia, Lanlan Cheng, Tian Jiang, Chao Liu, Shiqi Zhang, Honglin Hu, Fang Dai, Qiu Zhang, Yunxia Lu
Journal of International Medical Research.2021;[Epub] CrossRef - A STUDY TO EVALUATE THE EFFECT OF ANAEMIA IN TYPE-2 DIABETIC PATIENTS
Radhika Maheshwari, Divya J., J. Sahayaraj, Muthukrishnan R.
GLOBAL JOURNAL FOR RESEARCH ANALYSIS.2021; : 117. CrossRef - Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
Kyu Yeon Hur, Mee Kyoung Kim, Seung Hyun Ko, Miyeun Han, Dong Won Lee, Hyuk-Sang Kwon
Kidney Research and Clinical Practice.2020; 39(1): 32. CrossRef - Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
Kyu Yeon Hur, Mee Kyoung Kim, Seung Hyun Ko, Miyeun Han, Dong Won Lee, Hyuk-Sang Kwon
Diabetes & Metabolism Journal.2020; 44(1): 3. CrossRef - The prevalence of diabetic chronic kidney disease in adult Greek subjects with type 2 diabetes mellitus: A series from hospital-based diabetes clinics
Ilias N. Migdalis, Nikolaos Papanas, Athanasios E. Raptis, Ioannis M. Ioannidis, Alexios E. Sotiropoulos, George D. Dimitriadis
Diabetes Research and Clinical Practice.2020; 166: 108243. CrossRef - Proteinuria Is Associated with Carotid Artery Atherosclerosis in Non-Albuminuric Type 2 Diabetes: A Cross-Sectional Study
Jaehyun Bae, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
Journal of Clinical Medicine.2020; 9(1): 136. CrossRef - Renal status in elderly patients with type 2 diabetes
Kazunaga Takamatsu
Clinical and Experimental Nephrology.2020; 24(1): 53. CrossRef - The fat mass, estimated glomerular filtration rate, and chronic inflammation in type 2 diabetic patients
Tomáš Šálek, Alena Adamíková, Petr Ponížil
Journal of Clinical Laboratory Analysis.2020;[Epub] CrossRef - Insulin: Trigger and Target of Renal Functions
Ana F. Pina, Diego O. Borges, Maria João Meneses, Patrícia Branco, Rita Birne, Antonio Vilasi, Maria Paula Macedo
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef - Rate of kidney function decline and factors predicting progression of kidney disease in type 2 diabetes mellitus patients with reduced kidney function: A nationwide retrospective cohort study
Wisit Kaewput, Charat Thongprayoon, Api Chewcharat, Ram Rangsin, Bancha Satirapoj, Chalermrat Kaewput, Picha Suwannahitatorn, Tarun Bathini, Michael A. Mao, Liam D. Cato, Andrew M. Harrison, Pradeep Vaitla, Wisit Cheungpasitporn
Therapeutic Apheresis and Dialysis.2020; 24(6): 677. CrossRef - Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes
Jee Hee Yoo, Min Sun Choi, Jiyeon Ahn, Sung Woon Park, Yejin Kim, Kyu Yeon Hur, Sang-Man Jin, Gyuri Kim, Jae Hyeon Kim
Diabetes Technology & Therapeutics.2020; 22(10): 768. CrossRef - Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis
Jaehyun Bae, Namki Hong, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Yong-ho Lee
Journal of Clinical Medicine.2020; 9(3): 798. CrossRef - Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease—A Systematic Review and Meta-Analysis
Yao Hu, Min Lei, Guibao Ke, Xin Huang, Xuan Peng, Lihui Zhong, Ping Fu
Frontiers in Endocrinology.2020;[Epub] CrossRef - Treatment with Cinacalcet in Hemodialysis Patients with Severe Secondary Hyperparathyroidism, Influences Bone Mineral Metabolism and Anemia Parameters
Maria Aktsiali, Theodora Papachrysanthou , Ioannis Griveas, Christos Andriopoulos, Panagiotis Sitaras, Ioannis K. Triantafyllopoulos , George I. Lambrou
Current Drug Therapy.2020; 15(3): 249. CrossRef - Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome
Jung Beom Seo, Yeon-Kyung Choi, Hye-In Woo, Yun-A Jung, Sungwoo Lee, Seunghyeong Lee, Mihyang Park, In-Kyu Lee, Gwon-Soo Jung, Keun-Gyu Park
Diabetes & Metabolism Journal.2019; 43(6): 830. CrossRef - Glucometabolic characteristics and higher vascular complication risk in Korean patients with type 2 diabetes with non-albumin proteinuria
Yongin Cho, Yong-ho Lee, Eun Seok Kang, Bong-soo Cha, Byung-wan Lee
Journal of Diabetes and its Complications.2019; 33(8): 585. CrossRef - Assessment of kidney function and associated risk factors among type 2 diabetic patients
Moyad Jamal Shahwan, Nageeb Abdul galil Hassan, Rima Ahd Shaheen
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(4): 2661. CrossRef - Influence of diabetes mellitus on patients with lumbar spinal stenosis: A nationwide population-based study
Chang Kyu Lee, Sun Kyu Choi, Dong Ah Shin, Seong Yi, Yoon Ha, Keung Nyun Kim, Insoo Kim, Gregory W.J. Hawryluk
PLOS ONE.2019; 14(3): e0213858. CrossRef - Predictores de progresión de enfermedad renal en el paciente anciano
Manuel Heras Benito, Mª José Fernández Reyes Luis
Enfermería Nefrológica.2019; 22(1): 19. CrossRef
- Clinical Care/Education
- Self-Monitoring of Blood Glucose in Patients with Insulin-Treated Type 2 Diabetes Mellitus
-
Kyung-Soo Kim
-
Diabetes Metab J. 2018;42(1):26-27. Published online February 23, 2018
-
DOI: https://doi.org/10.4093/dmj.2018.42.1.26
-
-
4,013
View
-
65
Download
-
2
Web of Science
-
3
Crossref
-
PDFPubReader
-
Citations
Citations to this article as recorded by - Association between frequency of self-monitoring of blood glucose and glycemic control in patients with type 2 diabetes
Xiaoyan Sun, Xianghai Zhou, Shaobo Li, Linong Ji
Diabetes Research and Clinical Practice.2024; 209: 111027. CrossRef - Epidemiological profile and diabetes control of Type 1 Diabetes Mellitus patients in Karbala Governorate, Iraq
Abdul Razzaq Oleiwi Jasim, Noor Abdul Razzaq, Ali Thoulfikar A. Imeer, Rahem Mahdi Rahem, Abdul Amir H. Kadhum, Ahmed A. Al-Amiery
F1000Research.2023; 12: 409. CrossRef - Evaluating the impact of self‐monitoring of blood glucose frequencies on glucose control in patients with type 2 diabetes who do not use insulin: A systematic review and meta‐analysis
Yingqi Xu, David Hsien Yung Tan, Joyce Yu‐Chia Lee
International Journal of Clinical Practice.2019;[Epub] CrossRef
- The Clinical Characteristics of the Newly Diagnosed Early Onset (< 40 Years Old) Diabetes in Outpatients' Clinic
-
Kyung-Soo Kim, Hyun-Ju Oh, Ji-Woon Kim, Yeo-Kyung Lee, Soo-Kyung Kim, Seok-Won Park, Yoo-Lee Kim, Won-Keun Park, Yong-Wook Cho
-
Korean Diabetes J. 2010;34(2):119-125. Published online April 30, 2010
-
DOI: https://doi.org/10.4093/kdj.2010.34.2.119
-
-
4,886
View
-
52
Download
-
18
Crossref
-
Abstract
PDFPubReader
- Background
The prevalence of type 2 diabetes in young adults and adolescents has increased in the last decade according to the increasing obese population. The aim of this study was to examine the clinical characteristics of patients diagnosed with diabetes mellitus before the age of 40 years as compared with patients diagnosed at older ages. MethodsThis was a cross-sectional, retrospective study using data from 350 diabetic patients who were diagnosed with diabetes in an outpatient setting between January 2005 and December 2007. Patients were diagnosed according to the criteria set forth by the American Diabetes Association. We examined the clinical characteristics and laboratory data of the patients through review of medical records and compared the early-onset diabetic patients (< 40 years old) and the usual-onset diabetic patients (≥ 40 years old). ResultsThe frequency of early-onset diabetes and usual-onset diabetes were 31.1% (n=109) and 68.9% (n=241), respectively. The early-onset diabetic patients more often had a positive family history of diabetes; higher HbA1c, fasting glucose, and postprandial glucose levels; experienced typical symptoms more frequently; had microalbuminuria more frequently; and required insulin therapy as initial treatment more frequently as compared to usual-onset diabetic patients, and these differences were significant. Conversely, hypertension was significantly more common in the usual-onset diabetic patients. ConclusionIt could be concluded that we should control early onset diabetes more strictly to prevent its complication because early onset diabetic patients represented more severe hyperglycemia and had more prevalent microalbuminuria.
-
Citations
Citations to this article as recorded by - Clinical features of early-onset type 2 diabetes and its association with triglyceride glucose-body mass index: a cross-sectional study
Yanjuan Jiang, Xiaoyang Lai
Frontiers in Endocrinology.2024;[Epub] CrossRef - PERSPECTIVES OF CLINICAL EXPERTS ON THE CURRENT USAGE PATTERNS AND THE PREFERENCE OF VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES
Manjula S, KRISHNA KUMAR M
Innovare Journal of Medical Sciences.2024; : 1. CrossRef - The rising prevalence of type 2 diabetes among the youth in southern India—An ancillary analysis of the Secular TRends in DiabEtes in India (STRiDE‐I) study
Arun Nanditha, Priscilla Susairaj, Krishnamoorthy Satheesh, Arun Raghavan, Chamukuttan Snehalatha, Ambady Ramachandran
Journal of Diabetes.2024;[Epub] CrossRef - Clinical characteristics of patients with early-onset diabetes mellitus: a single-center retrospective study
Wenjing Dong, Saichun Zhang, Shiju Yan, Zhizhuang Zhao, Zengqiang Zhang, Weijun Gu
BMC Endocrine Disorders.2023;[Epub] CrossRef - Factors Associated with Chronic Disease and Health Care Utilization Among Young Adults in South Korea
Jongho Park, Yeaeun Kim
Population Health Management.2022; 25(3): 407. CrossRef - Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus
Md. Tanvir Kabir, Jannatul Ferdous Mitu, Raushanara Akter, Muhammad Furqan Akhtar, Ammara Saleem, Ahmed Al-Harrasi, Saurabh Bhatia, Md. Sohanur Rahman, Fouad Damiri, Mohammed Berrada, Md. Habibur Rahman
Environmental Science and Pollution Research.2022; 29(31): 46385. CrossRef - Characteristics of Glycemic Control and Long-Term Complications in Patients with Young-Onset Type 2 Diabetes
Han-sang Baek, Ji-Yeon Park, Jin Yu, Joonyub Lee, Yeoree Yang, Jeonghoon Ha, Seung Hwan Lee, Jae Hyoung Cho, Dong-Jun Lim, Hun-Sung Kim
Endocrinology and Metabolism.2022; 37(4): 641. CrossRef - The Difference in Risk Factors Between Adults With Early-Onset (<40 Years Old) Versus Late-Onset (≥40 Years Old) Type 2 Diabetes in a University Hospital From January 2015-December 2017
Marilyn Katrina C Caro, Elaine C Cunanan
Journal of Medicine, University of Santo Tomas.2022; 6(2): 1009. CrossRef - Comparison of clinical features, complication profile, and achievement of guideline targets in early- and late-onset type 2 diabetes patients from North India
Hamid Ashraf, Ahmad Faraz, Jamal Ahmad
International Journal of Diabetes in Developing Countries.2021; 41(3): 396. CrossRef - Questionnaire-based Survey of Demographic and Clinical Characteristics, Health Behaviors, and Mental Health of Young Korean Adults with Early-Onset Diabetes
Ji In Park, Hyunjeong Baek, Sang-Wook Kim, Ji Yun Jeong, Kee-Ho Song, Ji Hee Yu, Il Sung Nam-Goong, Eun-Hee Cho
Journal of Korean Medical Science.2021;[Epub] CrossRef - Association among Lifestyle Factors, Obesity, C-peptide Secretion, Metabolic Syndrome, and Cardiovascular Risk in Adults with Newly Diagnosed Type 2 Diabetes Mellitus: A Case Study
Sun-Young Kwon, Hye-Ja Park
Journal of Health Informatics and Statistics.2019; 44(2): 125. CrossRef - Type 2 diabetes in adolescents and young adults
Nadia Lascar, James Brown, Helen Pattison, Anthony H Barnett, Clifford J Bailey, Srikanth Bellary
The Lancet Diabetes & Endocrinology.2018; 6(1): 69. CrossRef - The relationship between age of onset and risk factors including family history and life style in Korean population with type 2 diabetes mellitus
Jin-Won Noh, Jin Hee Jung, Jeong Eun Park, Jung Hwa Lee, Kang Hee Sim, Jumin Park, Min Hee Kim, Ki-Bong Yoo
Journal of Physical Therapy Science.2018; 30(2): 201. CrossRef - Early-onset diabetes: an epidemic in China
Jiemin Pan, Weiping Jia
Frontiers of Medicine.2018; 12(6): 624. CrossRef - Distinct Predictors and Comorbidities in Early Onset Type 2 Diabetes Mellitus Among Asian Indians
Gadadharan Vijayakumar, Ganapathy K. Sreehari, Aswathi Vijayakumar, Abdul Jaleel
Metabolic Syndrome and Related Disorders.2017; 15(9): 458. CrossRef - A Predictive Model of Health Outcomes for Young People with Type 2 Diabetes
Sun Young Jung, Sook Ja Lee, Sun Hee Kim, Kyung Mi Jung
Asian Nursing Research.2015; 9(1): 73. CrossRef - An assessment of the impact of type 2 diabetes on the quality of life based on age at diabetes diagnosis
Jin Ook Chung, Dong Hyeok Cho, Dong Jin Chung, Min Young Chung
Acta Diabetologica.2014; 51(6): 1065. CrossRef - Characteristics, complications and management of a large multiethnic cohort of younger adults with type 2 diabetes
Katrien Benhalima, Soon H. Song, Emma G. Wilmot, Kamlesh Khunti, Laura J. Gray, Ian Lawrence, Melanie Davies
Primary Care Diabetes.2011; 5(4): 245. CrossRef
|
KDA
